symbol,statement_type,period_end,line_item,value
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Free Cash Flow,549520000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Repayment Of Debt,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Issuance Of Capital Stock,33910000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Capital Expenditure,-3480000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,End Cash Position,112150000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Beginning Cash Position,127600000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Effect Of Exchange Rate Changes,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Changes In Cash,-15450000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Financing Cash Flow,-116980000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Financing Charges,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Paid Cff,-9580000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Cash Dividends Paid,-132290000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Common Stock Issuance,33910000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Common Stock Issuance,33910000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Issuance Payments Of Debt,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Short Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Short Term Debt Payments,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Long Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Long Term Debt Payments,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Investing Cash Flow,-451470000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Investing Changes,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Received Cfi,78400000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Investment Purchase And Sale,53000000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of Investment,2609340000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Investment,-2556340000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Business Purchase And Sale,-936570000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Business,-936570000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net PPE Purchase And Sale,353700000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of PPE,357180000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of PPE,-3480000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Operating Cash Flow,553000000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Taxes Refund Paid,-81430000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Working Capital,55240000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Liabilities,44790000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Assets,7490000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Payable,21380000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Inventory,10000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Receivables,-22250000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Other Non Cash Items,-263740000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Stock Based Compensation,68040000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Provisionand Write Offof Assets,-2970000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Deferred Tax,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation And Amortization,81310000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Amortization Cash Flow,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation,81310000.0
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Investment Securities,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Sale Of PPE,
JAGSNPHARM.NS,cashflow,2025-03-31 00:00:00,Net Income From Continuing Operations,698590000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Free Cash Flow,349180000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Repayment Of Debt,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Issuance Of Capital Stock,56350000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Capital Expenditure,-2480000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,End Cash Position,127600000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Beginning Cash Position,110530000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Effect Of Exchange Rate Changes,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Changes In Cash,17070000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Financing Cash Flow,-89110000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Financing Charges,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Paid Cff,-8140000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Cash Dividends Paid,-130990000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Common Stock Issuance,56350000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Common Stock Issuance,56350000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Issuance Payments Of Debt,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Short Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Short Term Debt Payments,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Long Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Long Term Debt Payments,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Investing Cash Flow,-245480000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Investing Changes,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Received Cfi,73670000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Investment Purchase And Sale,-316670000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of Investment,1037400000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Investment,-1354070000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Business Purchase And Sale,0.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Business,0.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net PPE Purchase And Sale,-2480000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of PPE,0.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of PPE,-2480000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Operating Cash Flow,351660000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Taxes Refund Paid,-85130000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Working Capital,55390000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Liabilities,31870000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Assets,-33490000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Payable,-89820000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Inventory,53100000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Receivables,91540000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Other Non Cash Items,-77780000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Stock Based Compensation,133100000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Provisionand Write Offof Assets,7070000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Deferred Tax,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation And Amortization,16630000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Amortization Cash Flow,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation,16630000.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Investment Securities,
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Sale Of PPE,0.0
JAGSNPHARM.NS,cashflow,2024-03-31 00:00:00,Net Income From Continuing Operations,298690000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Free Cash Flow,463370000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Repayment Of Debt,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Issuance Of Capital Stock,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Capital Expenditure,-3180000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,End Cash Position,110530000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Beginning Cash Position,225260000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Effect Of Exchange Rate Changes,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Changes In Cash,-114730000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Financing Cash Flow,-4570000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Financing Charges,-3221000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Paid Cff,-4130000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Cash Dividends Paid,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Common Stock Issuance,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Common Stock Issuance,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Issuance Payments Of Debt,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Short Term Debt Issuance,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Short Term Debt Payments,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Long Term Debt Issuance,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Long Term Debt Payments,0.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Investing Cash Flow,-576710000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Investing Changes,-10000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Received Cfi,34280000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Investment Purchase And Sale,-620770000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of Investment,438170000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Investment,-1058940000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Business Purchase And Sale,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Business,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net PPE Purchase And Sale,9780000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of PPE,12960000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of PPE,-3180000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Operating Cash Flow,466550000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Taxes Refund Paid,-72760000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Working Capital,94960000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Liabilities,23600000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Assets,62630000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Payable,-19620000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Inventory,86860000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Receivables,-55560000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Other Non Cash Items,-2360000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Stock Based Compensation,87650000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Provisionand Write Offof Assets,4000000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Deferred Tax,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation And Amortization,11750000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Amortization Cash Flow,
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation,11750000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Investment Securities,-1480000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Sale Of PPE,-3590000.0
JAGSNPHARM.NS,cashflow,2023-03-31 00:00:00,Net Income From Continuing Operations,348080000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Free Cash Flow,58650000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Repayment Of Debt,-67880000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Issuance Of Capital Stock,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Capital Expenditure,-10490000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,End Cash Position,225260000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Beginning Cash Position,589430000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Changes In Cash,-364170000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Financing Cash Flow,-175520000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Financing Charges,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Paid Cff,-2850000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Cash Dividends Paid,-104790000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Common Stock Issuance,-15395000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Common Stock Issuance,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Issuance Payments Of Debt,-67880000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Short Term Debt Issuance,-67879000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Short Term Debt Payments,-67879000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Long Term Debt Issuance,-67880000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Long Term Debt Payments,-67880000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Investing Cash Flow,-257790000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Investing Changes,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Received Cfi,15460000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Investment Purchase And Sale,-268570000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of Investment,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Investment,-284486000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Business Purchase And Sale,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Business,
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net PPE Purchase And Sale,-4680000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of PPE,5810000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of PPE,-10490000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Operating Cash Flow,69140000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Taxes Refund Paid,-68730000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Working Capital,-114550000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Liabilities,-11140000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Assets,-56430000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Payable,-10750000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Inventory,-180000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Receivables,-29550000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Other Non Cash Items,-12600000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Stock Based Compensation,0.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Provisionand Write Offof Assets,-4450000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Deferred Tax,3288000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation And Amortization,15260000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Amortization Cash Flow,0.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation,15260000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Investment Securities,-11360000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Sale Of PPE,-850000.0
JAGSNPHARM.NS,cashflow,2022-03-31 00:00:00,Net Income From Continuing Operations,266420000.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Free Cash Flow,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Repayment Of Debt,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Issuance Of Capital Stock,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Capital Expenditure,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,End Cash Position,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Beginning Cash Position,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Changes In Cash,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Financing Cash Flow,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Financing Charges,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Paid Cff,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Cash Dividends Paid,-26200000.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Common Stock Issuance,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Common Stock Issuance,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Issuance Payments Of Debt,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Short Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Short Term Debt Payments,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Long Term Debt Issuance,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Long Term Debt Payments,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Investing Cash Flow,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Investing Changes,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Received Cfi,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Investment Purchase And Sale,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of Investment,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Investment,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Business Purchase And Sale,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Business,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net PPE Purchase And Sale,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of PPE,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of PPE,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Operating Cash Flow,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Taxes Refund Paid,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Working Capital,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Liabilities,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Assets,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Payable,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Inventory,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Receivables,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Other Non Cash Items,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Stock Based Compensation,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Provisionand Write Offof Assets,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Deferred Tax,-12330000.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation And Amortization,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Amortization Cash Flow,0.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation,
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Investment Securities,2505000.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Sale Of PPE,0.0
JAGSNPHARM.NS,cashflow,2021-03-31 00:00:00,Net Income From Continuing Operations,
